Navigation Links
Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Date:11/27/2012

d-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty of finding a suitable successor chief executive officer; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstanc
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
2. Vermillion Reports Third Quarter 2012 Results
3. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
4. Vermillion to Present at the 2012 Gateway Conference on September 6
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
7. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
8. Vermillion Announces CEO Succession Plan
9. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
10. Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
11. Positron Appoints Charles Conroy As Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, ... musculoskeletal healthcare, announced that it will be participating in ... at the Goldman Sachs offices in London ... About the Company Founded in 1927 and headquartered in ... a global leader in musculoskeletal healthcare.  We design, manufacture ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt ... at The Amazing Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at ... featured in media outlets as health authorities, and will present a two part seminar ...
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... a partnership agreement for quality market research promotion on the Internet. MarketPublishers.com ... Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager ...
Breaking Medicine News(10 mins):Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... and the Fastest Growing Healthcare Staffing Company with over 100 million Dollars ... ... Jackson Healthcare (JH) has been named the 5th largest healthcare staffing ... Compiled each year by SIA, firms are ranked on the list ...
... for their prolonged seizures with the sedative propofol may ... New research presented at CHEST 2008, the 74th annual ... Physicians (ACCP), shows that the use of propofol as ... (RSE), prolonged seizures that do not respond to initial ...
... look at the effect of neighborhood greenness on ... the Indiana University School of Medicine, Indiana University-Purdue ... that higher neighborhood greenness is associated with slower ... year period, regardless of residential density. , "Previous ...
... psychiatric cases in Michigan,s rural areas, particularly among children and ... colleges of Osteopathic Medicine and Human Medicine meet each week ... , On a typical morning, doctors in MSU,s Department of ... far away as Cadillac or Marquette all without leaving ...
... channel blockers could inhibit Plavix action, study says , , ... drugs, which are widely prescribed for coronary conditions, might ... new study says. , Calcium channel blockers appear to ... said the report by Austrian physicians published online Oct. ...
... Brachytherapy Treatment, ST. LOUIS, Oct. 27 ... to deliver radioactive seed therapy,in the prostate. The ... stabilizes the prostate during procedures. With the gland ... images to map,and confirm placement of radiation., ...
Cached Medicine News:Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 2Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 3Health News:Anti-seizure drug could be fatal 2Health News:Neighborhood greenness has long term positive impact on kids' health 2Health News:Neighborhood greenness has long term positive impact on kids' health 3Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2
... The Infinity Uric Acid single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Uric Acid reagent provides ...
... The Infinity Glucose Oxidase single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Glucose Oxidase reagent ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... provides a long shelf life that ...
... the profitability of your practice by seeing more ... VELO system you can turn a 14-18 patients ... day practice. By streamlining automated test sequences, youll ... technology is simple to learn; making it easy ...
Medicine Products: